Document is current
Any future updates will be listed below
-
Authors
Prattes, Juergen https://orcid.org/0000-0001-5751-9311
Giacobbe, Daniele R. https://orcid.org/0000-0003-2385-1759
Bassetti, Matteo https://orcid.org/0000-0002-0145-9740
Gangneux, Jean-Pierre https://orcid.org/0000-0002-4974-5607
Hoenigl, Martin https://orcid.org/0000-0002-1653-2824
,
Marelli, Cristina https://orcid.org/0000-0003-1510-1819
Signori, Alessio https://orcid.org/0000-0001-6289-9144
Dettori, Silvia
Cattardico, Greta
Frost, Jonas
Reizine, Florian https://orcid.org/0000-0002-9871-636X
-
Funding
Funding for this research was provided by:
Merck Sharp and Dohme Corp. (IIS 60879)
- License Information
-
More Information
Article History
Accepted: 27 June 2024
First Online: 9 July 2024
Declarations
:
: JP has received investigator-initiated grants from Pfizer, speaker fees from Pfizer, Gilead, Swedish Orphan Biovitrum and Associates of Cape Code and is a stoke holder of AbbVie Inc. and Novo Nordisk—all outside of the submitted work. MB has received funding for scientific advisory boards, travel, and speaker honoraria from Angelini, Astellas, BioMérieux, Cidara, Gilead, Menarini, MSD, Pfizer, Shionogi, Tetraphase and Nabriva—all outside of the submitted work. DRG reports investigator-initiated grants from Pfizer, Shionogi, BioMérieux, and Gilead Italia, and speaker/advisor fees from Menarini, Pfizer, and Tillotts Pharma—all outside of the submitted work. MH received research funding from Gilead, Astellas, MSD, IMMY, Mundipharma, Scynexis, Shionogi, F2G, and Pfizer—all outside of the submitted work. JPG received personal fundings for scientific advisory boards and speaker honoraria from Gilead, Mundipharma, Shionogi, and Pfizer—all outside of the submitted work.
: The main study protocol was approved by the local ethic committee at the Medical University of Graz, Austria (32-296 ex 19/20). IRCCS Ospedale Policlinico San Martino, Italy and University Hospital of Rennes, France provided data for the groups not receiving prophylaxis. Both centers obtained ethic committee approval by their local ethic committees [163/2020 with an amendment approved at May 5th 2022 (Genoa) and approval number 20.56 (Rennes)].
